RVTY

1. Top 5 Material Risks

• Market and Funding Sensitivity: Revvity’s quarterly revenue is highly dependent on the volume and timing of orders from pharmaceutical, laboratory, and government customers. Uncertainties regarding government funding proposals or budget cuts can cause customers to delay or reduce purchases, directly impacting Revvity's consolidated financial position and cash flows (10-K Item 1A).
• Global Economic and Political Conditions: As a global operator, Revvity is vulnerable to inflation, interest rate volatility, and trade barriers. Geopolitical conflicts, such as the situation in Ukraine, and trade protectionism can disrupt supply chains and interfere with operations in specific locations (10-K Item 1A).
• Technological Obsolescence and Innovation: Revvity operates in industries characterized by rapid technological change. Failure to accurately anticipate customer needs or successfully commercialize new products in a timely manner can lead to a loss of market share and a failure to meet revenue growth targets (10-K Item 1A).
• Acquisition and Integration Challenges: Revvity supplements internal growth through acquisitions. Risks include the inability to identify promising targets, high valuations, and difficulties in integrating acquired businesses, which may lead to asset impairments or the dilution of earnings (10-K Item 1A).
• Operational and Supply Chain Disruptions: Revvity relies on limited or single-source suppliers for critical raw materials and components. Disruptions in these supply chains, or in third-party package delivery services like UPS, FedEx, and DHL, can increase costs and damage customer relationships (10-K Item 1A).

2. Company-Specific Risks

• Intangible Asset Impairment: As of December 28, 2025, Revvity held $9.0 billion in net intangible assets. Adverse changes in business performance or valuation assumptions regarding its Life Sciences and Diagnostics segments could trigger impairment charges (10-K Item 1A).
• AI Deployment Uncertainty: Revvity is in the initial phases of expanding AI into core business functions. Flawed algorithms, biased datasets, or failure to train employees could lead to operational errors, increased costs, and potential legal or reputational damage (10-K Item 1A).
• Conflict Minerals Compliance: Revvity incurs additional costs to comply with SEC rules regarding conflict minerals (tantalum, tin, gold, tungsten). The potential lack of availability of these materials at competitive prices could increase production costs (10-K Item 1A).
• Leadership Succession: Revvity’s success depends on the continued service of executive officers and key technical personnel. The inability to successfully transition management roles could have a material adverse effect on operating results (10-K Item 1A).

3. Regulatory/Legal Risks

• Healthcare Regulation: The genetic screening market and broader healthcare industry are subject to extensive laws regarding fraud, abuse, and patient privacy. Non-compliance could result in fines, criminal damages, or exclusion from government healthcare programs (10-K Item 1A).
• Data Privacy: Revvity is subject to evolving global data privacy and information security laws. Failure to comply with these requirements in the U.S., E.U., or U.K. could lead to significant fines and enforcement actions (10-K Item 1A).
• Tax Law Changes: Revvity is exposed to changes in tax laws, including the OECD’s Base Erosion and Profit Shifting Pillar Two, which would impose a minimum corporate income tax rate of at least 15% (10-K Item 1A).
• Product Liability: The manufacture and sale of products expose Revvity to liability claims. If insurance coverage is inadequate or claims exceed policy limits, Revvity’s business could be adversely impacted (10-K Item 1A).

4. Financial Impact Map

Market/Funding Uncertainty → Revenue and Earnings Forecasts → Reductions in government funding or industrial spending lead to lower order volumes.

Tariffs and Trade Policy → Gross Margin → Fiscal year 2025 tariffs increased cost of revenue by approximately $25 million and reduced gross margin by approximately $20 million.

Debt Obligations → Cash Flow from Operations → Significant cash flow must be dedicated to principal and interest payments, reducing funds available for acquisitions and stock repurchases.

Intangible Assets → Results of Operations → Impairment of $9.0 billion in net intangible assets if reporting units fail to grow or valuation assumptions change.

Fixed Cost Structure → Operating Results → High proportion of fixed R&D and manufacturing costs means small declines in sales disproportionately affect quarterly operating results.